EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Ayurvedic Rasayanas as adjuncts in chemotherapy: Reviving the holistic paradigm in cancer care

Vidhi Jain, Jonah Sandrepogu, Prachi Khandelwal, Kanta Kumari, Sanjay Kumar Tiwari, Sonam Chauhan, Rupesh Vishwas Gangurde, Saba Naaz

Ayush Journal of Integrative Oncology · 2026-01 · 3 (1) · 7-18

DOI: 10.4103/ajio.ajio_1_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ayush Journal of Integrative Oncology, online erschienen am 16.04.2026. Verfasst von Vidhi Jain und 7 weiteren Autor:innen. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ayurveda, an ancient traditional system of medicine, has described cancer-like syndromes under the headings of Arbuda and Granthi . In this context, Rasayana therapy has been conceptualized as a rejuvenative and immunomodulatory strategy for increasing systemic resilience. Rasayanas have been classically prescribed for their uses in augmenting Ojas , reviving Agni , correcting Dhatu kshaya , and managing the overall physiological imbalance. The objective of this review is to critically assess the Ayurvedic rationale of Rasayana therapy and explore its potential application as an adjunct therapy in patients undergoing chemotherapy. The classical Ayurvedic concepts were critically assessed in conjunction with the modern preclinical and clinical research data on selected Rasayana drugs and formulations. There is some experimental and preclinical data to suggest that certain Rasayana drugs such as Ashwagandha (Withania somnifera), Guduchi (Tinospora cordifolia), Amalaki (Emblica officinalis), Shatavari (Asparagus racemosus), and compound preparations like Chyawanprasha may have a role in reducing the toxicities of chemotherapy, modulating the immune system, reducing oxidative stress, and improving the quality of life. However, the existing data are still inconclusive and varied. Rasayana therapy could provide some supportive benefits as an adjunct to conventional chemotherapy. However, rigorous randomized controlled trials, standardized formulations, and safety profiling are needed before any conclusive clinical recommendations can be made. A combination of traditional Ayurvedic concepts with modern oncological research could help provide a more holistic approach to cancer management.

Zitieren

APA

Jain, V., Sandrepogu, J., Khandelwal, P., Kumari, K., Tiwari, S. K., Chauhan, S., Gangurde, R. V., & Naaz, S. (2026). Ayurvedic Rasayanas as adjuncts in chemotherapy: Reviving the holistic paradigm in cancer care. Ayush Journal of Integrative Oncology, 3(1), 7-18. https://doi.org/10.4103/ajio.ajio_1_26

Vancouver

Jain V, Sandrepogu J, Khandelwal P, Kumari K, Tiwari SK, Chauhan S, et al. Ayurvedic Rasayanas as adjuncts in chemotherapy: Reviving the holistic paradigm in cancer care. Ayush Journal of Integrative Oncology. 2026;3(1):7-18. doi:10.4103/ajio.ajio_1_26

BibTeX
@article{Jain2026,
  author = {Jain, Vidhi and Sandrepogu, Jonah and Khandelwal, Prachi and Kumari, Kanta and Tiwari, Sanjay Kumar and Chauhan, Sonam and Gangurde, Rupesh Vishwas and Naaz, Saba},
  title = {Ayurvedic Rasayanas as adjuncts in chemotherapy: Reviving the holistic paradigm in cancer care},
  journal = {Ayush Journal of Integrative Oncology},
  year = {2026},
  volume = {3},
  number = {1},
  pages = {7--18},
  doi = {10.4103/ajio.ajio_1_26}
}
Kostenlos starten →